Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

Overview of attention for article published in New England Journal of Medicine, May 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 9 news outlets
blogs: 5 blogs
policy: 2 policy sources
twitter: 41 X users

patent: 28 patents
facebook: 15 Facebook pages
wikipedia: 3 Wikipedia pages
googleplus: 2 Google+ users

Citations

dimensions_citation: 1242 Dimensions

Readers on

mendeley: 1084 Mendeley
citeulike: 1 CiteULike

Summary News Blogs Policy documents X Patents Facebook Wikipedia Google+ Dimensions citations

So far, Altmetric has seen 6 policy documents that reference this research output.

elexacaftor/tezacaftor/ivacaftor and ivacaftor

Cited by Canadian Agency for Drugs and Technologies in Health on 23 Sep 2022

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

elexacaftor / tezacaftor / ivacaftor and ivacaftor

Cited by Canadian Agency for Drugs and Technologies in Health on 03 Nov 2021

elexacaftor / tezacaftor / ivacaftor and ivacaftor

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Nov 2021

lumacaftor/ivacaftor

Cited by Canadian Agency for Drugs and Technologies in Health on 12 Oct 2018

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity, including 2 additional policy documents.